Table 3.

Microbiological Outcome of Patients Who Received Ceftolozane/Tazobactam and Those Who Received the Standard of Care

Outcome	Ceftolozane/Tazobactam (n = 47)	Standard of Care (n = 50)	P Value
Microbiologically documented infection	13 (28)	12 (24)	.68
Microbiological response at EOIV			.86
Persistence	1/13 (8)	1/12 (8)
Eradication	11/13 (85)	9/12 (75)
Presumed eradication	0/13 (0)	1/12 (8)
Indeterminate	1/13 (8)	1/12 (8)
Microbiological response at TOC			.64
Persistence	0/13 (0)	1/12 (8)
Eradication	3/13 (23)	2/12 (17)
Presumed eradication	8/13 (62)	9/12 (75)
Indeterminate	2/13 (15)	0/12 (0)
Microbiological response at LFU			.33
Persistence	0/13 (0)	1/12 (8)
Eradication	2/13 (15)	3/12 (25)
Presumed eradication	81/3 (62)	8/12 (67)
Indeterminate	3/13 (23)	0/12 (0)
Relapse	0/12 (0)	0/11 (0)

Data are presented as No. of patients (%) unless otherwise indicated.

Abbreviations: EOIV, end of intravenous therapy; LFU, late follow-up; TOC, test of cure.